# US 2015/0148401 A1 · Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148401 A1
- Document ID: US20150148401A1
- Status: Published application
- Kind: A1
- Application number: 14/237,838
- Filed: 2012-08-09
- Published: 2015-05-28
- Earliest claimed: 2011-08-09
- Assignees: Fred Huchinson Cancer Research Center
- Inventors: Masafumi Toyoshima; Carla Grandori
- Web page: https://patentgrep.com/patent/US20150148401A1

## CPC

- A61K 31/65: Tetracyclines
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention generally relates to methods for identifying and using anticancer therapeutic agents and, more particularly, to methods for identifying and using inhibitors of genes for inhibiting the growth and/or proliferation of MYC-driven tumor cells relative to normal cells.

## Claims

### Claim 1

A method for inhibiting the growth and/or proliferation of a MYC-driven tumor cell comprising the step of contacting the tumor cell with at least one inhibitor that inhibits the gene function of at least one of the genes listed in Table 2.

### Claim 2 (depends on 1)

The method of claim 1, wherein the MYC-driven tumor cell is at least one of the following: a neuroblastoma tumor, a metastatic neuroblastoma tumor, a medulloblastoma, a lymphoma, a rhabdomyosarcoma, a melanoma, a lung cancer, a liver cancer, a breast cancer, a colon cancer, a prostate cancer, an ovarian cancer, or Burkitt's lymphoma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tumor cell is contacted in vitro.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tumor cell is contacted in vivo in a mammalian subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the inhibitor is a small molecule inhibitor that inhibits the function of the gene product.

### Claim 6 (depends on 1)

The method of claim 1, wherein the inhibitor interferes with the transcription of mRNA from the gene.

### Claim 7 (depends on 1)

The method of claim 1, wherein the inhibitor interferes with production or expression of the functional gene product of the gene.

### Claim 8 (depends on 1)

The method of claim 1, wherein the gene is selected from the genes listed in Table 1.

### Claim 9 (depends on 1)

The method of claim 1, wherein the gene is selected from the group consisting of ALDOA, CECR2, IGF2R, PAK6, PES1, RAD21, REV1L, SUV39H1, TIE1 .

### Claim 10

A method of treating a subject suffering from a tumor comprising MYC-driven tumor cells, comprising administering to the subject an amount of a composition comprising an inhibitor that inhibits the gene function of at least one of the genes listed in Table 2 and is effective to inhibit the growth and/or proliferation of the MYC-driven tumor cells.
